REGN · Full Picture

REGENERON PHARMACEUTICALS, INC. — the full picture

Trailing window · 2026-05-11 to 2026-08-09

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Competition and Market Share · Competition & market sharePriority 37
    quote_verified
    Analysts and reports note new biosimilar competition for Eylea as a challenge for Regeneron.
  2. Securities Fraud Litigation · Litigation & settlementsPriority 37
    1 forward row(s); quote_verified
    A securities class action lawsuit has been filed on behalf of Regeneron investors after its stock plummeted almost 10% because Regeneron allegedly misled investors regarding the success of its Phase III Fianlimab-Libtayo clinical trial.
  3. Intellia Gene-Editing Partnership · Partnerships & JVsPriority 36
    quote_verified
    Intellia reported positive Phase 3 HAELO data for lonvoguran ziclumeran (lonvo-z) showing an 87% reduction in attacks versus placebo and no serious adverse events.
  4. CytomX Collaboration Expansion · Partnerships & JVsPriority 33
    1 forward row(s); quote_verified
    CytomX completed enrollment for its Varseta-M Phase 1 CRC monotherapy trial with 113 patients and expects data by year-end 2026, with a registrational study planned for 1H 2027.
  5. Revenue Performance and Mix · Revenue growth & mixPriority 30
    quote_verified
    Regeneron reported Q2 2026 EPS of $14.29 and revenue of $4.29 billion, beating analyst expectations.
  6. Capital Return Program · Buybacks & dividendsPriority 26
    quote_verified
    Regeneron confirmed a quarterly dividend and updated on share repurchases in connection with its Q2 and H1 2026 results.

Threads by pillar

Revenue & Demand Priority 30 · 1 thread

Capital & Balance Sheet Priority 26 · 1 thread

Strategy & Portfolio Priority 39 · 2 threads

Legal, Regulatory & Policy Priority 37 · 1 thread

Macro & Market Conditions Priority 37 · 1 thread